| This week's sponsor is FierceBiotech’s Drug Development Forum. | | FierceBiotech’s Drug Development Forum – September 19-21, 2016 Join leading biotech professionals in the first-ever Drug Development Forum in Boston. Discover the latest trends, challenges, and innovations in the biotech industry. Sign up by July 29, 2016 and save $200 on registration.
Register now |
| Welcome to FierceLifeSci Weekly Digest, your Friday roundup of the biggest and most popular stories from each of our publications. | |
|
Top Stories Of The Week Monday, July 11, 2016 While several drugmakers may be circling coveted buyout target Medivation, so far, Sanofi is the only one that’s come through with a bid. But that could all be changing soon. Read more from FiercePharma Friday, July 8, 2016 Theranos has received notice from the Centers for Medicare & Medicaid Services of specific impositions of sanctions due to a 2015 survey of the Newark, CA, lab, which include banning CEO Holmes from operating the lab for two years. Read more from FierceMedicalDevices Monday, July 11, 2016 Two sides of one coin will keep diabetes drug sales on the upswing--big time--through 2025. The disease is growing fast globally, and doctors are pushing harder on blood-sugar control. That means sales of $59.4B by then, with GLP-1 drugs like Novo Nordisk's Victoza and Eli Lilly's Trulicity growing faster than any other class, analysts say. Read more from FiercePharmaMarketing Wednesday, July 13, 2016 Researchers at the Mayo Clinic have figured out a new way to beat metastatic cancer in a mouse model using a combination therapy that targets the immune system. The therapy is now being pursued in clinical trials and may hold promise for patients with advanced cancers such as pancreas, breast, colorectal and melanoma cancer. Read more from FierceBiotechResearch Wednesday, July 13, 2016 Already the world’s best-selling vaccine, Pfizer’s Prevnar 13 got yet another boost Tuesday with an expanded FDA approval in adults aged 18 to 49. Read more from FierceVaccines Thursday, July 14, 2016 The FDA has placed four Chinese and Indian generic drug facilities on the so-called “Red List” that bans them from shipping products to the U.S. for failing to pay required fees and not meeting identification requirements. Read more from FiercePharmaManufacturing Wednesday, July 6, 2016 Merck KGaA has given Orange Business Services responsibility for redesigning its global computer network. The agreement tasks Orange with making Merck KGaA’s network infrastructure less complex, while also taking steps to facilitate collaboration between staffers working across 200 locations. Read more from FierceBiotechIT Monday, July 11, 2016 Military hospitals in China are reportedly offering unapproved immunotherapy and stem cell treatments, promising miracle cures at steep fees. Read more from FiercePharmaAsia Tuesday, July 12, 2016 Amgen said the FDA has approved its Pushtronex, an on-body infusor with a prefilled cartridge designed to give a single monthly dose of statins in fighting high cholesterol. Read more from FierceDrugDelivery Monday, July 11, 2016 Just one month after Zoetis reported a better-than-expected first quarter, Bill Ackman’s Pershing Square Capital Management sold off 6 million shares of the company, it disclosed to the SEC in a recent filing. The hedge fund has now cut its stake in Zoetis from a high of 8% to about 3.8%. Read more from FierceAnimalHealth Events NOVEMBER 16-17, 2016 | BOSTON, MA | Presented By Speid Associates | MAY 24-26, 2016 | TEL AVIV, ISRAEL | Presented By BIOMED | MAY 18-19, 2016 | SAN DIEGO, CA | Presented By CBI | JUNE 6-9, 2016 | SAN FRANCISCO, CA | Presented By BIO | |
